Motegrity, Resolor(prucalopride)
Motegrity, Prucalopride, Resolor (prucalopride) is a small molecule pharmaceutical. Prucalopride was first approved as Resolor on 2009-10-14. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation. It is known to target 5-hydroxytryptamine receptor 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Motegrity, Prucalopride (discontinued: Prucalopride)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| motegrity | New Drug Application | 2025-07-17 |
| prucalopride | ANDA | 2026-07-31 |
| prucalopride succinate | ANDA | 2025-07-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| constipation | — | D003248 | K59.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
74 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | — | K59.0 | 6 | 8 | 15 | 5 | 5 | 37 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | 1 | 1 | — | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | 1 | 1 | — | 2 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | 2 | — | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | 1 | 1 | — | 2 |
| Gastrointestinal hemorrhage | D006471 | — | K92.2 | — | — | 1 | 1 | — | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | 1 | — | 1 |
| Celiac disease | D002446 | EFO_0001060 | K90.0 | — | — | — | 1 | — | 1 |
| Intestinal diseases | D007410 | — | K63.9 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ileus | D045823 | — | K56.7 | — | 2 | 2 | — | — | 4 |
| Intestinal pseudo-obstruction | D007418 | EFO_1000988 | K56.0 | — | 1 | 1 | — | — | 2 |
| Postoperative complications | D011183 | — | — | — | — | 2 | — | — | 2 |
| Colonic polyps | D003111 | — | K63.5 | — | — | 1 | — | 1 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 1 |
| Critical illness | D016638 | — | — | — | — | 1 | — | — | 1 |
| Opioid-induced constipation | D000079689 | — | — | — | — | 1 | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyspepsia | D004415 | EFO_0008533 | K30 | 1 | 1 | — | — | 1 | 2 |
| Deglutition disorders | D003680 | — | R13.1 | — | 1 | — | — | 1 | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | — | 4 | 4 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 3 | 3 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 2 | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 2 | 2 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 2 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
| Gastrointestinal motility | D005769 | — | — | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Prucalopride |
| INN | prucalopride |
| Description | Prucalopride is a member of benzamides. |
| Classification | Small molecule |
| Drug class | sulpride derivatives and analogs |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 179474-81-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL117287 |
| ChEBI ID | — |
| PubChem CID | 3052762 |
| DrugBank | DB06480 |
| UNII ID | 0A09IUW5TP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR4
HTR4
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Resolor – Shire
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,708 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,545 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use